This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

JDRF's "Kids For A Cure" Are Living Proof That A Cure For Type 1 Diabetes Is Within Reach

Inspirational kids from across Canada descend on Parliament Hill to advocate for expanded clinical trial network for diabetes research.

OTTAWA, Nov. 27, 2012 /CNW/ - Today, inspirational children from across Canada who live every day with type 1 diabetes (T1D) are in Ottawa to meet with Members of Parliament and Senators, as part of JDRF's Kids for a Cure Day.  These 40 Living Proof Champions and their families will discuss the challenges they face living with type 1 diabetes and the importance of expanding the JDRF Canadian Clinical Trial Network (JDRF CCTN) to all parts of the country.

JDRF's Kids for a Cure Day in Ottawa includes meetings with parliamentarians, a team appearance at the House of Commons Standing Committee on Health, and a lunchtime speech from Minister of National Defence Peter MacKay.

"It's an honour to share this day with such a remarkable group of children," said Andrew McKee, President and CEO, JDRF Canada.  "Every one of these kids is an embodiment of this year's theme - Living Proof.  They demonstrate the challenges of living with type 1 diabetes and show how research makes a difference in better treatment, curing and preventing this disease.  Through JDRF CCTN innovative research, we are accelerating solutions for the management, care, and cure of type 1 diabetes. "

"We have come to Ottawa today to share our stories with MPs and with each other, and to encourage everyone we meet to support finding a cure for type 1 diabetes, " said Megan Beamish, 14, of Halifax, who is serving as national co-chair of Kids for a Cure. "I was diagnosed when I was ten years old, and I use a pump to control my diabetes.  While I try not to let type 1 diabetes hold me back, every day I hope they find a cure for this disease; not just for me, but for my family and everyone around me that the disease also affects. "

"I've been moved by the stories of kids from my own constituency and across Canada who live with type 1 diabetes and I'm proud to help them in any way I can," said Patrick Brown, MP ( Barrie, ON), Chair of the All-Party Juvenile Diabetes Caucus.  "I know my colleagues on all sides of the House of Commons will be equally inspired and will continue to show their support for finding a cure."

About T1D T1D, the most severe form of diabetes, is a non-preventable autoimmune disease that strikes children and adults suddenly and lasts a lifetime. More than 300,000 Canadians and their families suffer from this disease and are faced with its devastating complications. i

Unlike type 2 diabetes, T1D cannot be prevented by diet, exercise or medication. Living with the disease demands constant blood testing and regulating. Someone living with T1D requires approximately 1,500 needles and 2,200 finger-pokes each year to test their blood sugar. ii

Insulin is not a cure for diabetes, nor does it prevent its eventual complications. iii

About JDRF JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all

people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs